Evidence map›Paper›PMID 41690989›Full record

ArticleNature communications2026

Depression of tryptophan may contribute to adverse effects of naproxen.

Soumita Ghosh, Nicholas F Lahens, Kayla Barekat, Soon-Yew Tang, Katherine N Theken, Emanuela Ricciotti, Arjun Sengupta, Robin Joshi, Weiming Hu, Frederic D Bushman and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Soumita GhoshInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas F LahensInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3965-5624
Kayla BarekatInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Soon-Yew TangInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8364-0342
Katherine N ThekenDepartment of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Emanuela RicciottiDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6971-3215
Arjun SenguptaDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-2210-1876
Robin JoshiInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Weiming HuDivision of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4740-4056
Aalim WeljieDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7145-4494
Tilo GrosserInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tilo.grosser@uni-bielefeld.de.ORCID http://orcid.org/0000-0001-8569-8396
Garret A FitzGeraldInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. garret@upenn.edu.ORCID http://orcid.org/0000-0002-5885-6819

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2M
NCATS NIH HHS UL1 TR001878NIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544
6 · The paper itself

Abstract

Non-steroidal anti-inflammatory drugs are popular choices for the mitigation of pain and inflammation; however, they are accompanied by adverse effects in the gastrointestinal and cardiovascular systems. Identifying biomarkers and mechanisms for early gastrointestinal or cardiovascular disease detection is desirable. Here we compare the effects of placebo, naproxen, a traditional NSAID, and celecoxib, a cyclooxygenase 2 inhibitor and find a decrease in tryptophan and kynurenine levels in the plasma of healthy volunteers who receive naproxen. We further validate this result in mice. Depression of tryptophan is independent of inhibition of either cyclooxygenase but rather, is due to the displacement of bound tryptophan by naproxen. Supplementation of tryptophan in naproxen-treated mice rescues fecal blood loss and inflammatory gene expression driven by IL-1β in the heart. Furthermore, tryptophan also rescues changes in genes that are reflective of inflammation and tissue damage in the gut.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalNaproxenTryptophanAnimalsCelecoxibCyclooxygenase 2 InhibitorsHumansInflammationInterleukin-1betaMaleMiceMice, Inbred C57BLAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2 InhibitorsInterleukin-1betaNaproxenTryptophan

Identifiers

PMID41690989
PMCPMC13018223

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.